Watson Pharmaceutical (NYSE:WPI) closed Wednesday's negative trading session at $52.44. In the past year, the stock has hit a 52-week low of $37.26 and 52-week high of $53.75. Watson Pharmaceutical stock has been showing support around $51.41 and resistance in the $53.95 range. Technical indicators for the stock are Bullish and S&P gives WPI a positive 4 STARS (out of 5) buy rating. For a hedged play on this stock, look at the May '11 $50.00 covered call for a net debit in the $48.14 area. That is also the break-even stock price for this trade. This covered call has a duration of 121 days, provides 8.20% downside protection and an assigned return rate of 3.86% for an annualized return rate of 11.66% (for comparison purposes only). A lower-cost hedged play for this stock would use a longer term call option in place of the covered call stock purchase. To use this strategy look at going long the WPI Jan '12 $35.00 call and selling the May '11 $50.00 call for a total debit of $13.65. The trade has a lifespan of 121 days and would provide 7.23% downside protection and an assigned return rate of 9.89% for an annualized return rate of 30% (for comparison purposes only). Watson Pharmaceutical does not pay dividends at this time.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment